AI stock analysis · Biotechnology · Last analyzed Aug 18, 2026
Compass Score
3.0/5
Call
Hold
Price
$4.26
AI Target
$13.33 +212.6%
AI Analyst Summary
C4 Therapeutics is a clinical-stage biotech pioneering targeted protein degradation (TPD) via its TORPEDO® platform, with near-unanimous analyst conviction (7 Buy, 0 Sell) and a consensus price target implying over 200% upside from current levels. The bull thesis rests on pipeline optionality — particularly its CFT8634 (BRD9 degrader for synovial sarcoma) and oncology collaborations — which could unlock substantial value upon clinical readouts. The primary risk is the company's pre-profitability status: with a negative forward P/E and minimal revenue growth of 2.8% YoY, the stock is entirely dependent on clinical execution and partnership milestones.
Catalysts
CFT8634 (BRD9 degrader) clinical data readout in synovial sarcoma — a high-unmet-need indication where early signals could serve as a significant re-rating catalyst.
New or expanded collaboration and licensing agreements leveraging the TORPEDO® platform, which could provide non-dilutive capital and validate the degrader technology.
Pipeline advancement of additional degrader candidates into IND-enabling or Phase 1 studies, broadening the platform's addressable oncology market and de-risking single-asset concentration.
Fundamentals
PeN/A (loss-making) · 1.0/5
No trailing P/E available; company is pre-profitability with a negative forward P/E of -4.3x, indicating ongoing net losses with no near-term path to GAAP profitability.
PegN/A · 3.0/5
PEG ratio is unavailable due to negative earnings. Scored neutrally per guidelines, as no growth-adjusted valuation multiple can be calculated.
Analyst RatingStrong Buy consensus (1.1) · 5.0/5
Extremely bullish analyst sentiment with a consensus rating of 1.1 (7 Buy / 0 Hold / 0 Sell across 6+ analysts), mapping to the highest possible score on the 1–5 analyst rating scale.
Earnings growth is not meaningful given ongoing losses. Revenue growth of 2.8% YoY is minimal, likely reflecting limited collaboration revenue. No positive earnings trajectory is evident.
Price Target Beat3 of 4 quarters beat · 2.0/5
Only 4 quarters of EPS beat history available, with 3 of 4 beats. Scored conservatively at 2 due to insufficient 8-quarter history; the limited sample prevents a higher confidence score.
ManagementMixed — consistent EPS beats but no earnings growth · 3.0/5
Management has beaten EPS estimates in 3 of 4 recent quarters, suggesting reasonable cost discipline, but the company remains deeply loss-making with minimal revenue growth. Analyst conviction is high, providing modest confidence in capital allocation.
● See the full picture
Get today's top-scored picks, ranked for you.
Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.
Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →
Not financial advice.
Compass is an analytical tool, not a registered investment adviser or broker-dealer.
Scores and recommendations are generated by AI, may be inaccurate or out of date, and are
not investment, financial, legal, or tax advice. Investing involves risk, including loss of
principal. Do your own research and consult a licensed financial professional.
About Compass.